The Patients First: Continuous Improvement in Care Outcomes "CIC Cancer" project will implement an innovative program of research that places cancer patients first. A co-design strategy involving consumers, clinicians, health services and researchers that will measure outcomes important to patients using the International Consortium for Health Outcome Measures (ICHOM) standard sets, identify key deficits in care pathways, generate and trial new interventions and implement findings rapidly. This project will directly improve the lives of those diagnosed with cancer.


Health care systems worldwide are in the midst of an historic transition. To achieve the best outcomes for patients, while curbing costs, all stakeholders are promoting a shift to a more transparent, value-based approach to service delivery, payment, and policy. This project brings together service providers, leading researchers and consumers to create a “self-improving health service”.

Involving consumers, clinicians, health services, and researchers, the CIC Cancer Project seeks to bring value based healthcare (VBHC) to public and private settings in Western Australia (WA). This will be achieved through better highlighting variations in outcomes that are important for people diagnosed with cancer, which at present are not routinely measured. The project will combine the range of clinical measures that are largely already collected with additional, patient reported measures that will feed back into the clinical management processes. These measures will help determine subsequent needs for clinical intervention and provide clarity of the ‘down-stream’ effects of existing treatments that may assist inform others of the benefits and disadvantages of these existing treatments. This project will measure outcomes important to patients using ICHOM datasets for breast, prostate, colorectal and lung cancer, and develop related tools for ovarian cancer patients – a less common and poorer outcome disease. Should opportunities and funding become available it may also be possible to explore other cancers.